纳洛酮治疗慢阻肺并Ⅱ型呼吸衰竭的疗效观察  

The clinical observation of naloxone in treating chronic obstructive pulmonary disease with type Ⅱ respiratory failure

作　　者：谢艳丽[1] 王以炳[1] 李玉磊[1] 夏蕾[1] 杨玉梅[1] 刘莉敏[1] 

机构地区：[1]武汉科技大学附属天佑医院呼吸内科,武汉430064

出　　处：《临床肺科杂志》2009年第9期1181-1182,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的观察纳洛酮在慢阻肺(COPD)并Ⅱ型呼吸衰竭患者中的疗效。方法选80例COPD并Ⅱ型呼吸衰竭的患者,随机分成两组,即治疗组和观察组,每组各40例。两组均对原发病给予积极的抗感染、解痉、平喘、祛痰、纠正水电解质平衡及对症、支持治疗,其中治疗组给予纳洛酮0.8mg+生理盐水10ml静推2/日,连用4d。对比两组病人治疗前后血气分析pH、PaCO2、PaO2、SaO2,神志改变及住院时间的变化。结果治疗组给予纳洛酮静推后,其神志改善明显早于观察组,治疗前后血气分析四项指标明显好转,平均住院时间明显缩短,与对照组相比,差异有显著统计学意义(P<0.05)。结论纳洛酮在慢阻肺COPD并Ⅱ型呼吸衰竭的救治中安全,有效。Objective To observe the clinical effectiveness of naloxone in treating the patients with chronic obstructive pulmonary disease （COPD） and the type II respiratory failure, and to explore the important role of naloxone preliminarily. Methods 80 patients with COPD and type II respiratory failure were randomly divided into two groups ： the treatment group and the control group, with 40 patients in each group. The patients in both groups were given the same treatment plans such as anti-infective, spasmolytic, antiasthmatic, expectorant, maintaining water and electrolyte balance, symptomatic and supportive care and so on. However, for the patients of the treatment group, naloxone 0. 8 mg with saline 10 ml were administered by intravenous injection twice a day as additional treatment, for four days. The pH, PaC02, PaO2 , SaO2 , mind changes and the length of stay were compared between these two groups after the treatment. Results After given naloxone the patientstnind improvement was significantly earlier than that of the control group＇s patients. Moreover as the treatment group, the four indicators of blood gas analysis had a remarkable improvement and the average length of stay was significantly shorter. There was a significant difference between two groups （P 〈 0. 05 ）. Conclusion Naloxone given to the patients with COPD and type II resniratorv failure for the treatment is safe and effective.

关 键 词：纳洛酮(NLX) 慢阻肺(COPD) Ⅱ型呼吸衰竭 β-内啡肽(β—EP) 

分 类 号：R563.9[医药卫生—呼吸系统] R563.8[医药卫生—内科学]